Ayala entered into an option to license agreement with Novartis for its investigational agent AL102 in multiple myeloma.
Ayala entered a license agreement with Novartis
![](https://ibf.fund/wp-content/uploads/2019/02/c26_1800x392.2018416T154941-e1549307472987-500x300.jpg)
Ayala entered into an option to license agreement with Novartis for its investigational agent AL102 in multiple myeloma.